The Bottleneck
For biopharmaceutical innovators, the first step is always the most critical: identifying the right biological target. Selecting a target that is genetically or causally linked to disease doubles the likelihood that a drug candidate will reach regulatory approval. Yet, traditional target identification is a slow, multi-year process often plagued by high failure rates.
The challenge isn’t a lack of data. it is data complexity and noise. Modern life science companies are sitting on massive volumes of disparate, short and wide datasets, including proprietary data, preclinical assay results, proprietary genomic sequencing, and historical clinical trial data, as well as public datasets featuring multi-omic repositories (genomics, transcriptomics, proteomics, metabolomics), real-world evidence, and deep literature networks.
Generic black-box AI models struggle with biological data because they were never built to handle biological non-linearity, sample variations, or incomplete datasets. They identify correlations, but correlation does not equal causation.
Systematic Analysis
At BullFrog AI, we bridge the gap between computational biology and actionable therapeutics. Powered by our proprietary bfLEAP® platform, we help life science organizations move beyond standard bioinformatics. We turn raw data into a clear, explainable roadmap for target discovery and optimization.
bfLEAP® excels at uncovering subtle biological signatures, the hidden biomarkers, that define distinct patient subgroups. By mapping these biomarkers early in discovery, we help you optimize your drug development strategy to align with the patient populations most likely to respond to your therapeutic candidate.
Seamlessly integrate genomics, transcriptomics, proteomics, metabolomics, and real-world clinical data.
Rank and de-risk biological targets based on genetic validation, causal disease linkage, and mechanistic feasibility.
Unearth complex, multi-modal biomarkers that traditional linear statistics miss.
Evaluate how your proprietary molecules may interact with novel targets to discover entirely new therapeutic opportunities for existing assets.
Request a feasibility study with our data or your own to explore what’s possible.
